Values First Advisors, Inc. Agenus Inc Transaction History

Values First Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	BUY	$0.53 - $0.93 $35,123 - $61,632	66,271 Added 24.56%	336,100 $194,000
Q4 2023 Jan 18, 2024	BUY	$0.63 - $1.14 $12,327 - $22,307	19,568 Added 7.82%	269,829 $223,000
Q3 2023 Nov 08, 2023	SELL	$1.12 - $1.88 $2,086 - $3,502	-1,863 Reduced 0.74%	250,261 $282,000
Q2 2023 Aug 02, 2023	BUY	$1.31 - $2.04 $7,329 - $11,413	5,595 Added 2.27%	252,124 $403,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.95 $10,393 - $21,145	7,168 Added 2.99%	246,529 $374,000
Q4 2022 Jan 20, 2023	BUY	$2.02 - $3.25 $1,710 - $2,752	847 Added 0.36%	239,361 $0
Q3 2022 Dec 02, 2022	BUY	$1.96 - $3.14 $19,625 - $31,440	10,013 Added 4.38%	238,514 $489,000
Q2 2022 Jul 20, 2022	BUY	$1.3 - $2.64 $297,051 - $603,242	228,501 New	228,501 $443,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.